利伐沙班、达比加群对急性心肌梗死后左心室血栓患者的治疗效果分析
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Analysis of the therapeutic effect of rivaroxaban and dabigatran on left ventricular thrombus patients after acute myocardial infarction
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
    摘要:

    目的:研究利伐沙班、达比加群对急性心肌梗死(AMI)后左心室血栓(LVT)患者的治疗效果。方法:以行急诊经皮冠状动脉介入术(PCI)的129例AMI后LVT患者为研究对象,按照不同治疗方案分成华法林组(初始剂量2.5 mg, 1次/d,根据国际标准化比值调整)、利伐沙班组(10 mg, 1次/d)、达比加群组(110 mg, 2次/d),每组各43例。对比三组患者3个月内LVT溶解率及不良心血管事件(MACE)发生率、出血事件发生率、心肌酶谱指标[肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)、肌钙蛋白Ⅰ(cTnⅠ)]、肝功能指标。结果:利伐沙班组、达比加群组LVT溶解率高于华法林组(P<0.05);利伐沙班组、达比加群组MACE发生率均低于华法林组(P<0.05),但利伐沙班组、达比加群组间比较,差异无统计学意义(P>0.05);利伐沙班组、达比加群组出血事件发生率均低于华法林组(P<0.05);治疗后7 d、1个月,利伐沙班组、达比加群组心肌酶谱指标CK-MB、LDH、cTnⅠ均低于华法林组(P<0.05),但利伐沙班组、达比加群组间比较差异无统计学意义(P>0.05);三组患者治疗前后各时间点肝功能指标ALT、AST、TB比较,差异均无统计学意义(P>0.05)。结论:利伐沙班、达比加群在治疗AMI后LVT患者的效果相当,且均优于华法林,以上两种药均可促进LVT溶解,降低MACE和出血事件发生风险,促进心肌功能恢复,且治疗安全性良好。

    Abstract:

    Objective:To explore on the therapeutic effect of rivaroxaban and dabigatran on left ventricular thrombus(LVT)patients after acute myocardial infarction(AMI).Methods:129 post AMI LVT patients who underwent emergency per-cutaneous coronary intervention(PCI)were divided into three groups according to different treatment methods:warfarin group(initial dose 2.5 mg,once a day,adjusted according to international standard ratio),rivaroxaban group(10 mg,once a day),and dabigatran group(110 mg,twice a day),with 43 patients in each group.The LVT dissolution rate,incidence rates of major ad-verse cardiovascular events(MACE),incidence rates of bleeding events,myocardial enzyme spectrum indexes[creatine kinase isoenzyme(CK-MB),lactate dehydrogenase(LDH),troponin Ⅰ(cTnⅠ)]and liver function indexes were compared among the three groups of patients within 3 months.Results:The dissolution rate of LVT in rivaroxaban group and dabigatran group was higher than that in warfarin group(P<0.05).The incidence rates of MACE were lower in rivaroxaban group and dabigatran group than those in warfarin group(P<0.05),but there were no statistical differences between rivaroxaban group and dabigat-ran group(P>0.05).The total incidence rate of bleeding events in rivaroxaban group and dabigatran group was lower com-pared with that in warfarin group(P<0.05).After 7 days and 1 month of treatment,the myocardial enzyme spectrum indexes such as CK-MB,LDH and cTnⅠ were lower in rivaroxaban group and dabigatran group compared to warfarin group(P<0.05),but no statistical differences were shown between rivaroxaban group and dabigatran group(P>0.05).The differences in liver function indexes such as ALT,AST and TB were not statistically significant among the three groups of patients at each time point before and after treatment(P>0.05).Conclusion:Rivaroxaban and dabigatran are equally effective in treating LVT pa-tients after AMI,and both are superior to warfarin.Both drugs can promote LVT dissolution,reduce the risk of MACE and bleeding events,promote myocardial function recovery,and have good treatment safety.

    参考文献
    相似文献
    引证文献
引用本文

刘雪瑜;林珍;欧阳山丹;杜江涛;徐昕;林利仙;.利伐沙班、达比加群对急性心肌梗死后左心室血栓患者的治疗效果分析[J].川北医学院学报,2025,40(10):1350-1353.

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-11-03
  • 出版日期:
文章二维码